These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22943618)

  • 41. Guidelines for evaluation of drugs for use in man. Report of a WHO scientific group.
    World Health Organ Tech Rep Ser; 1975; (563):1-59. PubMed ID: 803745
    [No Abstract]   [Full Text] [Related]  

  • 42. [Clinical pharmacokinetics and drug therapy in pediatrics].
    Prandota J; Panków-Prandota L
    Pediatr Pol; 1979 Jul; 54(7):773-80. PubMed ID: 394111
    [No Abstract]   [Full Text] [Related]  

  • 43. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range.
    Sandhu P; Vogel JS; Rose MJ; Ubick EA; Brunner JE; Wallace MA; Adelsberger JK; Baker MP; Henderson PT; Pearson PG; Baillie TA
    Drug Metab Dispos; 2004 Nov; 32(11):1254-9. PubMed ID: 15286054
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Microassay of drugs and modern measurement techniques.
    Millership JS
    Paediatr Anaesth; 2011 Mar; 21(3):197-205. PubMed ID: 21320232
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Accelerator mass spectrometry for biomedical research.
    Brown K; Dingley KH; Turteltaub KW
    Methods Enzymol; 2005; 402():423-43. PubMed ID: 16401518
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An AMS method to determine analyte recovery from pharmacokinetic studies with concomitant extravascular and intravenous administration.
    Lappin G; Seymour M; Young G; Higton D; Hill HM
    Bioanalysis; 2011 Feb; 3(4):407-10. PubMed ID: 21338260
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pediatric critical care pharmacodynamics.
    Dionne R; McManus C
    Crit Care Nurs Clin North Am; 1993 Jun; 5(2):367-75. PubMed ID: 8398042
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pediatric pharmacology: is treatment of children preceded by an adequate investigation?].
    Rubio González A; Suárez Ochoa J; Azanza Perea J; Honorato Pérez J
    An Esp Pediatr; 1989 May; 30(5):359-62. PubMed ID: 2667410
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The application of human phase 0 microdosing trials: A systematic review and perspectives.
    Svendsen P; El-Galaly TC; Dybkær K; Bøgsted M; Laursen MB; Schmitz A; Jensen P; Johnsen HE
    Leuk Lymphoma; 2016; 57(6):1281-90. PubMed ID: 26428262
    [TBL] [Abstract][Full Text] [Related]  

  • 50. European Bioanalysis Forum recommendation: scientific validation of quantification by accelerator mass spectrometry.
    Higton D; Young G; Timmerman P; Abbott R; Knutsson M; Svensson LD
    Bioanalysis; 2012 Nov; 4(22):2669-79. PubMed ID: 23210650
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic analysis of 14C-ursodiol in newborn infants using accelerator mass spectrometry.
    Gordi T; Baillie R; Vuong le T; Abidi S; Dueker S; Vasquez H; Pegis P; Hopper AO; Power GG; Blood AB
    J Clin Pharmacol; 2014 Sep; 54(9):1031-7. PubMed ID: 24805288
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current challenges in pediatric drug development.
    Adamson PC
    Clin Adv Hematol Oncol; 2008 Dec; 6(12):883-4. PubMed ID: 19209138
    [No Abstract]   [Full Text] [Related]  

  • 53. Development of medicines for children in Europe: ethical implications.
    Saint Raymond A; Brasseur D
    Paediatr Respir Rev; 2005 Mar; 6(1):45-51. PubMed ID: 15698816
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pediatric clinical pharmacology.
    Martin E; Guignard JP
    Helv Paediatr Acta; 1982; 37(6):509-17. PubMed ID: 7166486
    [No Abstract]   [Full Text] [Related]  

  • 55. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61134-5. PubMed ID: 16237860
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002.
    Balakrishnan K; Grieve J; Tordoff J; Norris P; Reith D
    J Clin Pharmacol; 2006 Sep; 46(9):1038-43. PubMed ID: 16920899
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ethical challenges in neonatal research: Summary report of the ethics group of the newborn drug development initiative.
    Baer GR; Nelson RM;
    Clin Ther; 2006 Sep; 28(9):1399-407. PubMed ID: 17062312
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians.
    de Leon J; Spina E; Diaz FJ
    J Clin Psychopharmacol; 2009 Jun; 29(3):201-5. PubMed ID: 19440070
    [No Abstract]   [Full Text] [Related]  

  • 59. Pediatric Age Groups and Approach to Studies.
    Job KM; Gamalo M; Ward RM
    Ther Innov Regul Sci; 2019 Sep; 53(5):584-589. PubMed ID: 31311309
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pediatric microdose and microtracer studies using 14C in Europe.
    Turner MA; Mooij MG; Vaes WH; Windhorst AD; Hendrikse NH; Knibbe CA; Kõrgvee LT; Maruszak W; Grynkiewicz G; Garner RC; Tibboel D; Park BK; de Wildt SN
    Clin Pharmacol Ther; 2015 Sep; 98(3):234-7. PubMed ID: 26095095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.